Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
University of Chicago
Chicago, IL
Fellowship - Hematology-Oncology
2021
McGaw Medical Center of Northwestern University
Chicago, IL
Chief Residency - Internal Medicine
2018
McGaw Medical Center of Northwestern University
Chicago, IL
Residency - Internal Medicine
2017
University of Missouri School of Medicine
Columbia, MO
MD - Medicine
2014
Northwestern University
Evanston, IL
BA - Economics
2010
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026 Jul 28.
PMID: 42520193
Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms.
Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms. Int J Hematol. 2026 Jul 21.
PMID: 42481866
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 Jul 02; JCO2600347.
PMID: 42391582
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026. J Natl Compr Canc Netw. 2026 Jul; 24(7).
PMID: 42425157
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy. Leuk Lymphoma. 2026 Jun 11; 1-9.
PMID: 42281276
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. J Natl Compr Canc Netw. 2026 Jun; 24(6):222-229.
PMID: 42297017
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study. JACC Adv. 2026 Jun; 5(6 Pt 2):102821.
PMID: 42312783
Exercises in Clinical Reasoning: Applying High-Value Care When the Counts Don't Add Up.
Exercises in Clinical Reasoning: Applying High-Value Care When the Counts Don't Add Up. J Gen Intern Med. 2026 Apr 20.
PMID: 42010105
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leuk Lymphoma. 2026 Apr 09; 1-8.
PMID: 41954351
Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.
Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis. Cardiooncology. 2026 Mar 11.
PMID: 41814386